Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.

Expert opinion on drug metabolism & toxicology - 1 Jan 2021

Illés Árpád, Pinczés László Imre, Egyed Miklós

Abstract excerpt

INTRODUCTION: Polycythemia vera (PV) is a Philadelphia chromosome-negative chronic myeloproliferative neoplasm (MPN). A newly developed PV treatment option, ropeginterferon alfa-2b, contains recombinant human alfa monoisomer as an active ingredient, resulting in a novel pharmacologic profile and improved tolerability. Efficacy studies conclude remarkable long-term hematological response and sustained JAK2V617F...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Polyethylene Glycols

Share to Recombinant Proteins

Share to Survival Rate

Source

Identifiers

PMID: 33118413
DOI: 10.1080/17425255.2021.1839050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.PMID 33118413Read ↗

Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.Semantic proximity Read ↗

Real-life use of ropeg-interferon α2b in Polycythemia Vera: patient selection and clinical outcomesSemantic proximity Read ↗

Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.Semantic proximity Read ↗

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivoSemantic proximity Read ↗

The advantages and risks of ruxolitinib for the treatment of polycythemia vera.Semantic proximity Read ↗

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?Semantic proximity Read ↗

[Sustained hematologic complete response after discontinuation of ropeginterferon alfa-2b in patients with polycythemia vera].Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.